Net sales and license revenues declined in 2024, but cost reductions and new capital from rights issues improved liquidity. Strategic partnerships and licensing agreements advanced, positioning Bioextrax for commercial growth in bioplastics and sustainable materials.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.